Podcasts about hexavalent

For twenty years, Los Alamos National Laboratory (LANL) has struggled to contain the cancer-causing hexavalent chromium plume in the regional drinking water aquifer below the nuclear weapons site. The horizontal and vertical reach of the deep plume covers an area of unknown size and the depth of the contamination is unknown. --- Support this podcast: https://podcasters.spotify.com/pod/show/ccnsupdate/support

Twenty years ago, the hexavalent chromium plume was discovered in the regional aquifer 1,000 feet below ground surface at Los Alamos National Laboratory (LANL). Since then the debate about how to remove the dangerous hexavalent chromium from the regional drinking water aquifer has been ongoing between LANL, the New Mexico Environment Department, and the public. --- Support this podcast: https://podcasters.spotify.com/pod/show/ccnsupdate/support

In an utterly confusing move, Los Alamos National Laboratory (LANL) released an environmental assessment for public review and comment that claims it contains the final remedy for the cleanup of the hexavalent chromium plume in the regional drinking water aquifer. --- Support this podcast: https://podcasters.spotify.com/pod/show/ccnsupdate/support

CCNS provided the following response to a recent Santa Fe New Mexican Our View: “In response to Stop Stalling: Clean up chromium plume, no one is stalling. The plume does need immediate attention and does need to be analyzed with a computer model that everyone can use. The consequences of getting the cleanup of the toxic hexavalent chromium plume wrong would be disastrous. --- Support this podcast: https://podcasters.spotify.com/pod/show/ccnsupdate/support

Did you know that in 2008 the Environmental Protection Agency (EPA) designated the 3,000 square mile Española Basin System as a Sole Source Drinking Water Aquifer? One ongoing concern is that Los Alamos National Laboratory (LANL) sits on its western edge, near the Valles Caldera. And a recent dispute between the New Mexico Environment Department and the Department of Energy about the LANL hexavalent chromium plume, which is being pushed deeper into the regional drinking water aquifer, highlights the need for state agencies to have the resources to protect it. Hexavalent chromium is a known human carcinogen. --- Support this podcast: https://podcasters.spotify.com/pod/show/ccnsupdate/support

Los Alamos National Laboratory plans to prepare an environmental assessment to address the hexavalent chromium contamination in the deep regional drinking water aquifer. In comments submitted this week, the Communities for Clean Water recommended that LANL conduct a more detailed environmental impact statement in order to protect the regional drinking water aquifer and the Environmental Protection Agency-designated Española Basin Sole Source Aquifer from the migrating contamination. --- Support this podcast: https://podcasters.spotify.com/pod/show/ccnsupdate/support

Amy and Jen discuss a government guidance document published in the past year which reviews the Hepatitis B selective immunisation pathway for pregnant people and newborns. We look at this guidance from the perspective of health visitors in practice - what do you need to know? What should be happening, what actually IS happening and what do you need to do when this crops up on your caseload? As ever we love to hear from you with any comments or thoughts by email on iamahealthvisitor@gmail.com. Resources and Further Reading: I am a HV episode on the Hexavalent vaccine: https://soundcloud.com/iamahealthvisitor/changes-to-the-immunisation-schedule-august-2017-episode-2 Guidance Document - Hepatitis B antenatal screening and selective neonatal immunisation pathway. https://www.gov.uk/government/publications/hepatitis-b-antenatal-screening-and-selective-neonatal-immunisation-pathway

Episode 0251 - Rocks, Exotic Materials and Safety Daniel is here this week.  We're talking about an epic B squad move involving a pile of rocks, Daniels fabrication segment which enlightens with some safety, exotic materials and then some feedback with human combustion!  What could possibly go wrong?   Show Notes: Friction welding https://www.youtube.com/watch?v=-aEuAK8bsQg Hexavalent Chromium: https://en.wikipedia.org/wiki/Hexavalent_chromium   DPP Mfg Emailing Resumes to DPP MFG: dppmfg@gmail.com daniel.k@dppmfg.com Website: http://www.dppmfg.com/ Facebook: https://www.facebook.com/DPPmfgemporia/     Thanks for listening, downloading and subscribing. For questions, comments or complaints please e-mail us at: Hosts@BsquadHotrod.com And if you really want to help us out give us a review in your podcast app.

“VAXELIS may be used to complete the hepatitis B vaccination series following 1 or 2 doses of other hepatitis B vaccines, in infants and children born of HBsAg-negative mothers and who are also scheduled to receive the other antigens in VAXELIS. However, data are not available on the safety and effectiveness of VAXELIS in such infants and children. Administration of VAXELIS following previous doses of Inactivated Polio Vaccine (IPV) VAXELIS may be administered to infants and children who have received 1 or 2 doses of IPV and are also scheduled to receive the other antigens in VAXELIS. However, data are not available on the safety and effectiveness of VAXELIS in such infants and children. Administration of VAXELIS following previous doses of Haemophilus b Conjugate Vaccines VAXELIS may be administered to infants and children who have received 1 or 2 doses of H. influenzae type b Conjugate Vaccine and are also scheduled to receive the other antigens in VAXELIS. However, “Each 0.5 mL dose contains 319 mcg (0.319 mg ) aluminum from aluminum salts used as adjuvants.Active ingredients: inactivated bacteria of diphtheria, tetanus, pertussis, Hib, and inactivated hepatitis B and polio viruses. The bacteria and viruses in VAXELIS are not alive and do not cause disease. • Other ingredients: aluminum salts, polysorbate 80, glutaraldehyde, formaldehyde, bovine serum albumin, neomycin, streptomycin, polymyxin B, ammonium thiocyanate, yeast protein, and waterwww.vaccinesafety.edu 

In this episode of On the Line, Products Finishing editor-in-chief Scott Francis sits down with Bryan Leiker and Justin Guzman representing the Metal Finishers Association of California to discuss the impact of California's recently proposed transition deadlines for hexavalent chromium plating to trivalent chromium alternatives.

In this episode of On the Line, Products Finishing editor-in-chief sits down with Mark Shario, executive vice president with Columbia Chemical to hear about the latest innovations in trivalent chromium plating technology.

Rachel Coyte is a PhD student at Duke University who is the leading author of the last two papers on the occurrence of hexavalent chromium and other contaminants in groundwater in NC. Rachel and Dr. Avner Vengosh have been researching and working on testing wells in NC for Hexavalent Chromium. Hexavalent chromium is a carcinogen made famous by the movie Erin Brockovich and is far more abundant in drinking water wells in North Carolina than previously thought, a new Duke University study finds. “About 90 percent of the wells we sampled had detectable levels of hexavalent chromium, and in many cases the contamination is well above recommended levels for safe drinking water. But our analysis clearly shows it is derived from natural sources” The current drinking water standard for chromium in the United States is 100 parts per billion. This is based on an assumption that most chromium contained in drinking water is composed of a less toxic form known as trivalent chromium. Only California has set a statewide standard of 10 parts per billion for the much more toxic hexavalent form. The bottom line is that we need to protect the health of North Carolinians from the naturally occurring threat of hexavalent chromium, while also protecting them from harmful contaminants such as arsenic and selenium, which our previous research has shown do derive from leaking coal ash ponds. With Rachel we talk about the effects of Hexavalent Chromium, where it's found, if it's man made or naturally occurring, if it can be filtered, and how people can protect themselves. Contact and connect with Rachel: rachel.coyte@duke.edu Rachel's articles on Hex Chrome: https://nicholas.duke.edu/news/hexavalent-chromium-widespread-nc-wells-not-linked-coal-ash https://sites.nicholas.duke.edu/avnervengosh/hexavalent-chromium-in-north-carolina/ Geogenic contaminants: https://www.eawag.ch/en/department/sandec/projects/wst/geogenic-contamination/ https://link.springer.com/chapter/10.1007/978-81-322-3745-7_8 NC health standards: https://deq.nc.gov/about/divisions/water-resources/planning/classification-standards/surface-water-standards https://deq.nc.gov/about/divisions/water-resources/water-resources-regulations Well water testing: https://ehs.ncpublichealth.com/oswp/wells-resources.htm https://epi.dph.ncdhhs.gov/oee/wellwater/howtotest.html Background Music Credits: https://www.youtube.com/c/mbbmusic https://soundcloud.com/mbbofficial https://www.instagram.com/mbb_music

Dan Longenette is a self-proclaimed "Chromosexual", he loves chrome that much. In fact, he would build his home around his garage if he could. We delve into Dan's deep affinity for cars.

We learn how to properly store and charge car batteries to extend product life with OPTIMA Batteries (@OptimaBatteries) eCare Manager, Jim McIlvaine. Then, we get technical about chrome with Metal Brite Polishing Owner, Mike Barr. Segment 1: Surviving the Seasons Segment 2: Charge It Segment 3: Psyched for SEMA Segment 4: Hexavalent vs. Trivalent Segment 5: Crazy for Chrome Segment 6: Chromosexual

Your car battery takes a beating all summer long. With winter right around the corner, can your battery survive the cold? We get ready to pick the brain of OPTIMA Batteries (@OptimaBatteries) expert, Jim McIlvaine. Plus, Dan sets up today's interview with our main chrome guru, Metal Brite Polishing's Mike Barr.

When it's cold outside, it takes more energy to get a car started. That's why many don't notice their car battery is going bad until winter sets in. OPTIMA Batteries (@OptimaBatteries) eCare Manager, Jim McIlvaine, says it's important to use a smart charger which tapers amperage and voltage throughout the charging cycle to ensure you get the most life out of your battery. For this tip and more, listen now.

SEMA is getting close and OPTIMA Batteries (@OptimaBatteries) is stepping up their trade show game. Jim McIlvaine gives us a sneak peek of OPTIMA's mobile marketing display, a converted semitrailer with a "bar" of virtual reality headsets. Learn more.

Have you ever noticed that some chrome has a yellowish hue? Our resident chrome expert and Owner of Metal Brite Polishing, Mike Barr, explains not all chrome plating is created equal. Find out the differences between hexavalent and trivalent.

Pitted pot metal is a cause for concern when buying a classic, but it's not an insurmountable problem. Metal Brite Polishing's Mike Barr explains the chrome restoration process.

Safe & Sound Episode 154: Hexavalent Chromium Dr. Kathleen MacMahon and Mr. Robert Park discuss NIOSH’s recent release “Criteria for a Recommended Standard: Occupational Exposure to Hexavalent Chromium”.

Alan, Rich, and Dickson discuss Edward Jenner's paper on cowpox vaccine, then move 200 years later to modern vaccines against norovirus, influenza H5N1, and more. Links for this episode: Norton Zinder, 83 (Reuters) Jenner's cowpox vaccine paper (Bartleby, Gutenberg) Norovirus VLP vaccine (NEJM) Plant-grown H5N1 VLP vaccine (Reuters, PLoS One) Plant-grown norovirus VLP Hexavalent pediatric vaccine TWiV on Facebook Letters read on TWiV 170

Background: Following the introduction of conjugate vaccines against invasive Haemophilus influenzae type b (Hib) disease in Germany, the incidence of Hib disease dramatically decreased. Hib conjugate vaccines were combined with diphtheria, tetanus and acellular pertussis antigens (DTaP/Hib) and gradually replaced by higher-valent vaccines, additionally incorporating inactivated polio virus and - since the end of 2000 - hepatitis B (DTaP-IPV-HB/Hib or hexavalent vaccines). Recently, an increasing incidence of invasive Hib disease in children and an increasing number of vaccine failures have been reported from some European countries, which coincided with the introduction of combination vaccines containing the acellular pertussis component. Previous data in Germany showed no such increase and vaccine effectiveness (VE) of DTaP/Hib and DTaP-IPV/Hib combination vaccines against invasive Hib disease was estimated to be high. Since Germany is the first country who introduced hexavalent vaccines, insufficient data on the impact of hexavalent vaccines on invasive Hib disease and on the VE against invasive Hib disease in children exist. Aim: To assess (1) annual numbers of Hib cases and vaccine failures of Hib vaccines before and after the introduction of hexavalent vaccines in German children, (2) annual incidences of invasive Hib disease before and after the introduction of hexavalent vaccines in German children and to estimate (3) VE of hexavalent vaccines against invasive Hib disease in German children. Subjects and Methods: Invasive Haemophilus influenzae (Hi) infections in children less than 10 years were ascertained from 1998 to 2004 through two independent nation-wide active surveillance systems, one hospital- and one laboratory-based. Species confirmation and capsular testing was performed in the national consulting laboratory for Hi. Cases were defined by any hospitalisation due to a systemic infection clinically compatible with an invasive Hi disease and with isolation of Hi from a normally sterile body site. Annual case numbers and incidences were adjusted for underreporting and for differences in the proportion of typed cases over time. VE was determined with a case-cohort approach using Cox regression with time-dependent covariates. In this analysis, Hib cases born between August 2000 and June 2003, aged 2 months or older and ascertained from August 2000 to December 2003 were included for case-cohort analysis and a ‘sub’-cohort of children born in the same time frame as the cases was randomly sampled in a nationwide immunisation survey. Children receiving two/three Hib doses (depending on vaccine type) in the first year of life, without booster, were defined as ‘fully primed’, children receiving a single dose in the second year of life, regardless of priming, as receiving a ‘2nd year dose’ and children receiving a booster dose at the age of 11 months or later following full priming as receiving the ‘full immunisation’. Results: In the two surveillance systems annual response rates since 1998 were >90%, the proportion of untyped Hi cases decreased from 25% of all reported cases in 1998 to 15% in 2004 and the proportion typed in the national consulting laboratory increased from 55% of all reported cases in 1998 to 70% in 2004. The annual number of Hi cases decreased from 51 in 1998 to 27 cases in 2004. Hib cases fluctuated between 28 in 1998 and 4 in 2004. Of all 117 Hib cases detected since 1998, 64 were not vaccinated and 52 were vaccinated at least once. 92% of the unvaccinated Hib cases and 53% of the vaccinated Hib cases could have received at least one (additional) dose if timing of general recommendations would have been followed. Of all vaccinated Hib cases, 12 had been vaccinated with at least one dose of a hexavalent vaccine. Overall annual incidence rates of Hi disease were relatively constant throughout the years 1998 through 2004 (0.8-0.4/100,000). Annual incidences of Hib disease ranged between 0.3 and 0.1 per 100,000 in 1998 and 2004, respectively, with the highest incidence in the 3-11 month age-group (1.7/100,000 in 2003). Adjustment for underreporting and differences in typing gave no evidence of an increasing trend of Hib disease in German children. Twenty-seven cases were eligible for VE calculation; 17 were unvaccinated and 10 vaccinated with hexavalent vaccines; of these, 5 received an incomplete primary series, 5 received the full primary series and none a 2nd year dose or the full immunisation before disease onset. In the immunisation survey, response rate was 63% and interviewed households were representative for age-eligible children in Germany according to geographical and social distributions. 1303 valid interviews of children born from 1 August 2000 onwards were available. Median age at vaccination with the complete primary series of hexavalent vaccines was 6.0 months and 14.4 months for the full immunisation. Effectiveness of hexavalent vaccines against invasive Hib infection was 75.5% (95% CI: 31.4-91.3) for incomplete primary series and 91.8% (95% CI: 73.6-97.5) for the full primary series. For the 2nd year dose - but no full immunisation - and full immunisation vaccine effectiveness was 100.0% (95% CI: 99.5-100.0 and 99.9-100.0, respectively). Conclusion: Four years after the introduction of hexavalent vaccines in Germany, there was no indication of increasing incidence of invasive Hib disease or increasing number of vaccine failures in children. Hexavalent vaccines continue to show the high effectiveness against invasive Hib disease observed for other DTaP-containing Hib vaccines in Germany. Sustained surveillance – especially for fully immunised children - should confirm protection induced by hexavalent vaccines.